Biomarkers as Surrogate Endpoints: Ongoing Opportunities for Validation

Journal of Law, Medicine and Ethics 47 (3):393-395 (2019)
  Copy   BIBTEX

Abstract

Surrogate endpoints are a common application of biomarkers to estimate clinical benefit in clinical trials, despite questions about reliability. This article discusses ongoing opportunities for their validation, in the context of a regulatory environment in which they are increasingly championed.

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 91,475

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

The ‘Big Picture’: The Problem of Extrapolation in Basic Research.Tudor M. Baetu - 2016 - British Journal for the Philosophy of Science 67 (4):941-964.
Analysis of Bioethical Problems Regarding Surrogate Conception in Japan.Masayuki Kodama - 2011 - Eubios Journal of Asian and International Bioethics 21 (1-2):34-36.
Biomarker Validation: Context and Complexities.Lisa M. McShane - 2019 - Journal of Law, Medicine and Ethics 47 (3):388-392.

Analytics

Added to PP
2019-09-28

Downloads
24 (#650,558)

6 months
20 (#128,456)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

No citations found.

Add more citations

References found in this work

No references found.

Add more references